NCT06046131 Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.
| NCT ID | NCT06046131 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de la Guadeloupe |
| Condition | Prostatic Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2023-02-28 |
| Primary Completion | 2039-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3,000 participants in total. It began in 2023-02-28 with a primary completion date of 2039-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The course and progression of prostate cancer is highly variable, depending on the individual characteristics, the aggressiveness of the disease at the time of diagnosis as well as the ethno-geographic origins of the individuals. The general objective of the project is to identify the clinical, genetic and environmental determinants (risk factors) of the evolution, progression and complications of the disease according to the treatment options. Identifying modifiable and non-modifiable prognostic determinants of disease progression is a major challenge. This knowledge will help guide treatment choices but also, especially in high-risk populations (high incidence of disease) to better tailor prevention policies and possibly screening .
Eligibility Criteria
Inclusion Criteria: Inclusion criteria: Adult patients with incident case of prostate cancer Patient consulting the University Hospital of Guadeloupe or the University Hospital of Rennes Patient who resides in the departments of Guadeloupe or Martinique or the community of Saint-Martin or in Britany Patient affiliated or beneficiary of the social security signed consent Exclusion Criteria: Physical or mental health judjed by the investigator as precluding participation in the research Protected adults (guardianship, curatorship, safeguard of justice).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06046131 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostatic Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06046131 currently recruiting?
Yes, NCT06046131 is actively recruiting participants. Contact the research team at valerie.soter@chu-guadeloupe.fr for enrollment information.
Where is the NCT06046131 trial being conducted?
This trial is being conducted at Rennes, France, Pointe-à-Pitre, Guadeloupe.
Who is sponsoring the NCT06046131 clinical trial?
NCT06046131 is sponsored by Centre Hospitalier Universitaire de la Guadeloupe. The trial plans to enroll 3,000 participants.